Addex ADX71441 Demonstrates Statistically Significant

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
137
Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain

Geneva, Switzerland, 9 January 2017 - Addex Therapeutics (SIX: ADXN), announced today that ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor demonstrated statistically significant efficacy in a highly translational preclinical model of chronic osteoarthritis pain.

ADX71441 and celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug were studied in the monosodium iodoacetate (MIA) model of chronic osteoarthritis pain for their anti-hyperalgesic effects. ADX71441 at doses of 0.3, 1, 3, and 15 mg/kg orally administered showed statistically significant efficacy 21 days post MIA administration. At 15 mg/kg the effect is similar to that observed with 30 mg/kg of celecoxib (P<0.01).

The study also demonstrated that ADX71943, a more peripherally restricted GABAB PAM compound, was more effective at early stages, presumably when the osteoarthritis pain is at a more inflammatory phase. While ADX71441, the more centrally active compound, was more effective at later stages, presumably when the osteoarthritis pain is at a more chronic neuropathic phase. Details of these data were published in European Journal of Pharmacology (Kalinichev et al, December 2016; available online).

"The efficacy demonstrated by ADX71441 in this chronic pain model, comparable to that obtained with the gold standard celecoxib, strongly supports the use of ADX71441 to treat chronic neuropathic pain," said Robert Lütjens, Head of Discovery at Addex. "ADX71441 has completed preclinical development and is scheduled to start Phase 1 this year."

"This recent publication in the European Journal of Pharmacology is a further demonstration of the quality of the science at Addex," said Tim Dyer, CEO of Addex. "While we focus on advancing ADX71441 in Phase 1 for addiction, we continue to profile other GABAB PAM compounds in multiple indications, including CMT1A neuropathy and pain."

GABAB receptor is clinically & commercially validated. Generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and French health authorities have approved its use for the treatment of alcoholism. Baclofen is also used off label for a number of other indications including overactive bladder (OAB), but its utility is limited due to variety of side effects and rapid clearance, requiring frequent administration of higher doses.

ADX71441 is a potent selective positive allosteric modulator (PAM) which potentiates GABA responses at the GABAB receptor. ADX71441 is a novel, first-in-class, oral, small molecule that demonstrated excellent preclinical efficacy and tolerability in rodent models of pain, anxiety, OAB, alcohol use disorders, nicotine dependence and in a non-human primate model of cocaine use disorder. ADX71441 has also proven efficacy in a genetic model of Charcot-Marie-Tooth Type 1A disease (CMT1A). ADX71441 has a different molecular mechanism from the generic drug baclofen in that it is a positive allosteric modulator, rather than an orthosteric agonist at the GABAB receptor, with a longer half-life, suitable for once daily administration. ADX71441 only acts when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and lead to less tolerance than direct agonists.

Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase 2A POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM for neurodegenerative diseases, mGluR7NAM for psychosomatic disorders and TrkBPAM for neurodegenerative disorders which are being advanced in collaboration with the Universities of Lausanne and Geneva under the Swiss CTI grant program; and mGluR3PAM which is being advanced in collaboration with Pierre Fabre Pharmaceuticals.

Contact: Tim Dyer Chief Executive Officer Addex Therapeutics Telephone: +41 22 884 15 61 Email: PR@addextherapeutics.com

Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 19

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 84

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 25

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 74

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 130

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 133

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 21

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Qfin Holdings Faces Securities Fraud Lawsuit Scrutiny

Updated Category News Views 23

Qfin Holdings Stumbles Under Legal Microscope Picture this—you're riding the stock market wave and then, out of nowhere, your investment gets hit by a sudden drop, leaving you scrambling for answers. That's the scenario investors in Qfin Holdings, Inc. (NASDAQ: QFIN) find themselves in after the company’s stock plunged by nearly 19%. Now, they're not just left...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 44

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading

Top 5 Most Recently Viewed Articles

Aura Minerals Inc. Successfully Issues New Brazilian Debentures

Updated Category News Views 55

Aura Minerals Inc. Successfully Secures Funding through Debenture Issuance Aura Minerals Inc. (TSX: ORA) has recently made waves in the financial sector by successfully concluding the public offering of its 2nd issuance of debentures. The company announced this development following previous communications made on several dates earlier this year, confirming the completion...

Continue Reading
Emerging Trends in Clinical Trials Matching Software Market

Updated Category News Views 266

Growth of the Clinical Trials Matching Software Market The landscape of clinical trials is continually evolving, with the clinical trials matching software market expected to reach an impressive USD 501.86 million. This expansion points to a noteworthy compound annual growth rate (CAGR) of 13.14% between 2025 and 2032. Significance of AI and EHR Integration Market...

Continue Reading
Greystone Housing Plans Earnings Call to Discuss Q1 Results

Updated Category News Views 155

Greystone Housing to Host Earnings Conference Call Greystone Housing Impact Investors LP (NYSE: GHI) has announced it will be hosting an important earnings conference call for investors. This event is set to take place on a Wednesday at 4:30 p.m. Eastern Time. The focus of the call will be on discussing the financial results from the first quarter of the year....

Continue Reading
Successful Toyota Dealership Sale in the Automotive Market

Updated Category News Views 864

Performance Brokerage Services Facilitates Dealership Transaction Performance Brokerage Services, a leader in dealership buy-sell activities, has announced the successful sale of Premier Toyota. The dealership changed ownership from Robert Fisher to Kevin Wuepper, showcasing the brokerage firm’s expertise in the automotive sector. The Journey of Premier Toyota Founded...

Continue Reading
Investigation Launched into Sealed Air Corporation's Shareholder Deal

Updated Category News Views 193

Understanding the Investigation of Sealed Air Corporation In recent news, the Ademi Firm has initiated a probe into Sealed Air Corporation (NYSE: SEE), focusing on their proposed transaction with CD&R. This investigation is crucial because it centers on possible violations of fiduciary duty and legal requirements by the company’s board. The goal is to ensure that...

Continue Reading